Integer (NYSE:ITGR) Releases FY 2025 Earnings Guidance

Integer (NYSE:ITGR) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 5.840-6.200 for the period, compared to the consensus EPS estimate of 6.070. The company issued revenue guidance of $1.8 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

Integer Trading Down 2.8 %

NYSE:ITGR traded down $3.76 during midday trading on Friday, reaching $131.46. 226,062 shares of the stock traded hands, compared to its average volume of 241,928. The stock has a market capitalization of $4.41 billion, a P/E ratio of 40.62, a PEG ratio of 1.82 and a beta of 1.13. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.09 and a current ratio of 3.28. The company has a fifty day moving average of $137.92 and a 200 day moving average of $132.31. Integer has a 12 month low of $98.63 and a 12 month high of $146.36.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing the consensus estimate of $1.46 by ($0.03). The firm had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. On average, research analysts predict that Integer will post 5.33 EPS for the current year.

Analysts Set New Price Targets

ITGR has been the topic of a number of recent analyst reports. Benchmark lifted their price objective on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday. Truist Financial lifted their price target on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Wells Fargo & Company restated an “overweight” rating and issued a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. Citigroup lifted their target price on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Finally, Oppenheimer downgraded shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $147.67.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.